Androfen LLC cites differences in test groups’ results to claim its testosterone-boosting supplement could “reduce body fat by over 200%,” but the Electronic Retailing Self-Regulation Program says the firm’s calculations likely will not add up for consumers.
Androfen should discontinue the claim for its eponymous-branded product because consumers can interpret it in a way not supported by...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?